Tarsus Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Tarsus Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $224.95 million for the year ending 2023.

  • Tarsus Pharmaceuticals, Inc. showed an increase of +213.9% in Cash And Cash Equivalents At Carrying Value from 2022 to 2023.
  • This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2024.
  • XBRL data for this metric is available from 2019 to 2023 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q3 2019: $337.0 thousand | Q1 2020: $55.89 million | Q2 2020: $53.14 million | Q3 2020: $86.33 million | Q1 2021: $156.18 million | Q2 2021: $176.74 million | Q3 2021: $183.80 million | Q1 2022: $175.01 million | Q2 2022: $245.36 million.
  • Over the full 5 years of available data (2019 to 2023), Tarsus Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 288.2%.
  • Historical annual values: Fiscal year 2023: $224.95 million | Fiscal year 2022: $71.66 million | Fiscal year 2021: $171.33 million | Fiscal year 2020: $168.13 million | Fiscal year 2019: $57.95 million.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: